Loading
A phase 2 trial of Psilocybin therapy in endometrial cancer, prostate cancer, gastric & gastro-oesophageal junction cancer, melanoma and pancreatic ductal adenocarcinoma, run by Psyence Australia Pty Ltd, now recruiting.
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder is a phase 2 interventional study registered as NCT07072728 by Psyence Australia Pty Ltd, with 87 participants planned, started 2025-10-01 and due to reach its primary completion in 2026-12-30. Interventions recorded: Psilocybin therapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Melanoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Melanoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/